As of November 6, 2026, 2 holders' latest Schedule 13D or 13G filings report owning 5% or more of Madrigal Pharmaceuticals, Inc. The largest reported stake is Paul A Friedman, M.D.'s, at 7.8%. 2 filings are on record since December 12, 2025 (Schedule 13D/A, December 12, 2025).
Sell to companies like Madrigal Pharmaceuticals, Inc? Enter your website and see 10 with a filed reason to buy from you this month. Free.
Opens in a new tab. No signup.
Madrigal Pharmaceuticals, Inc. has 2 Schedule 13D or 13G filings on record since 2025-12-12. 2 holders' latest filing reports 5% or more of common stock, par value $0.0001 per share. Each figure below is the holder's own, as filed, with the filing linked.
Holders
| Holder | Percent | Shares | Latest | Event date |
|---|---|---|---|---|
| Paul A Friedman, M.D. | 7.8% | 1,814,831 | SCHEDULE 13D/A, 2025-12-12 | 2025-12-10 |
| Rebecca Taub, M.D. | 7.8% | 1,814,831 | SCHEDULE 13D/A, 2025-12-12 | 2025-12-10 |
Holding shares or following this stake? See who's behind Madrigal Pharmaceuticals, Inc. and the warning signs.
Free to see. No signup.
Keep reading
More on Madrigal Pharmaceuticals, Inc. and the records around it.
Companies that share a holder
- Paul A Friedman, M.D. also filed stake reports on 1 other company: MADRIGAL PHARMACEUTICALS, INC. (Dec 2025)
- Rebecca Taub, M.D. also filed stake reports on 1 other company: MADRIGAL PHARMACEUTICALS, INC. (Dec 2025)
Watch Madrigal Pharmaceuticals, Inc.
Get an email when Madrigal Pharmaceuticals, Inc. files again: a new raise, a leadership change, a layoff or an IPO filing. One email first to confirm; nothing else until you click it. At most one a day, one click to stop. Free for up to 3 companies.
Want the whole picture on Madrigal Pharmaceuticals, Inc.?
Example from a real report (our sample on Target): “Target eliminated approximately 1,800 corporate positions, with around 1,000 employees receiving layoff notices and the remainder accounted for by eliminating open roles.” Source: NBC News
A Full Report on Madrigal Pharmaceuticals, Inc.: verified, sourced, every claim cited, ready in a few minutes. See pricing.
What the Full Report on Madrigal Pharmaceuticals, Inc. covers
The Short Answer
Which Company This Is
What They Do, And How The Money Works
Who Runs It, And How To Reach Them
The Money: Funding, Valuation, Runway
Who Pays Them, And Who They Are Up Against
Warning Bells
Sources
2 cited sources found
Plus the sections for what you are deciding, which you pick after ordering.
A real finished report, first screen. Opens in a new tab.
Not ready to order yet? Keep this snapshot.
Sends this preview to you once; we won't add you to any list
Voting and dispositive power, as filed
| Reporting person | Sole voting | Shared voting | Sole dispositive | Shared dispositive | Filing |
|---|---|---|---|---|---|
| Paul A Friedman, M.D. | 1,159,291 | 655,540 | 1,159,291 | 655,540 | SCHEDULE 13D/A, 2025-12-12 |
| Rebecca Taub, M.D. | 1,159,291 | 655,540 | 1,159,291 | 655,540 | SCHEDULE 13D/A, 2025-12-12 |
The latest filing identifies Madrigal Pharmaceuticals, Inc. by CUSIP 558868105 and gives its principal executive office as Four Tower Bridge, 200 Barr Harbor Drive, Suite 200, West Conshohocken, PA 19428 (SCHEDULE 13D/A, 2025-12-12).
Source of funds (Item 3)
No changes, except as set forth below. Each of Dr. Friedman and his spouse has received stock options, restricted stock and restricted stock unit awards from the Issuer in connection with their service as an officer and/or a member of the Board of Directors of the Issuer. In addition to the shares listed as beneficially owned in the table above, (i) Dr.Paul A Friedman, M.D., SCHEDULE 13D/A, 2025-12-12
No changes, except as set forth below. Each of Dr. Taub and her spouse has received stock options, restricted stock and restricted stock unit awards from the Issuer in connection with their service as an officer and/or a member of the Board of Directors of the Issuer. In addition to the shares listed as beneficially owned in the table above, (i) Dr.Rebecca Taub, M.D., SCHEDULE 13D/A, 2025-12-12
Purpose of Transaction (Item 4)
Paul A Friedman, M.D.
No changes, except that the Reporting Person no longer serves as Chairman of the Board and Chief Executive Officer of the Issuer; the Reporting Person continues to serve as a member of the Board of Directors of the Issuer.Item 4 of the SCHEDULE 13D/A filed 2025-12-12
Rebecca Taub, M.D.
No changes, except that the Reporting Person no longer serves as Chief Medical Officer of the Issuer; the Reporting Person serves as Senior Scientific and Medical Advisor of the Issuer and continues to serve as a member of the Board of Directors of the Issuer.Item 4 of the SCHEDULE 13D/A filed 2025-12-12
Timeline
| Filed | Holder | Percent | Filing |
|---|---|---|---|
| 2025-12-12 | Paul A Friedman, M.D. | 7.8% | SCHEDULE 13D/A |
| 2025-12-12 | Rebecca Taub, M.D. | 7.8% | SCHEDULE 13D/A |
Questions about who owns Madrigal Pharmaceuticals, Inc.
Who owns Madrigal Pharmaceuticals, Inc.?
On this page, 2 holders' latest ownership filings report 5% or more of Madrigal Pharmaceuticals, Inc.: Paul A Friedman, M.D. (7.8%, Schedule 13D/A, filed 2025-12-12) and Rebecca Taub, M.D. (7.8%, Schedule 13D/A, filed 2025-12-12).
Who are the largest shareholders of Madrigal Pharmaceuticals, Inc.?
By the share each holder's latest filing reports, the largest holders of Madrigal Pharmaceuticals, Inc. on this page are Paul A Friedman, M.D. (7.8%) and Rebecca Taub, M.D. (7.8%).
When did Paul A Friedman, M.D. buy into Madrigal Pharmaceuticals, Inc.?
The filings give report dates, not purchase dates. The earliest filing from Paul A Friedman, M.D. on this page is the Schedule 13D/A, filed 2025-12-12, reporting 7.8%. That earliest filing is itself an amendment, which updates an earlier report.
Is this an audit or a full list?
Neither. The ownership list on this page covers only Schedule 13D and 13G filings, which holders make once they own 5% or more of a class of shares (an amendment can report a stake that has since fallen below 5%); 2 such filings are shown here. It is not an audit and not a full cap table: holders who never reached 5% are not listed, and a stake can change after its latest filing.
Tools for this story
Each opens in a new tab, filled in for Madrigal Pharmaceuticals, Inc.. With no account yet, you sign up free and land on the result.
Where this comes from
Anyone who comes to own more than 5% of a class of a listed company's voting shares has to tell the SEC. A holder who may seek to change or influence the company files Schedule 13D, and has to say in Item 4, "Purpose of Transaction", what it intends to do. A holder with no such intent, such as many index and passive funds, may file the shorter Schedule 13G. Both are amended when the stake changes, including when it falls below 5%.
Every row here is one of those filings, linked to the filing itself. Percentages and share counts are exactly as the holder filed them, for the holder the filing names; an amendment showing a lower figure is shown as filed. Item 4 text is quoted word for word. Where a 13D's Item 4 contains a sentence stating a definite intent to influence the company, that sentence is marked and quoted; the page does not describe the holder or its motives beyond the words it filed. Nothing here is investment advice.